Immunotherapy for treating insect venom allergies.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the safety and effectiveness of immunotherapy for patients with hymenoptera venom allergy under real-life conditions. It involves a multicentric approach across various hospitals in Spain, where data will be collected prospectively from participants aged 14 and older who are sensitized to insect venom. The study will include controlled and spontaneous sting evaluations to assess the treatment's impact on allergic reactions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The study population consisted of allergic participants indicated for treatment with hymenoptera venom immunotherapy (Apis mellifera or Vespula spp.) according to standard clinical practice.
* Participants of both sexes aged 14 years or more.
* Participants who have not received immunotherapy with hymenoptera venom in the previous 5 years.
* Participants who have agreed to take part in the study and sign the informed consent form. In the case of minors, the patient's parent or guardian must also sign.

Exclusion Criteria:

* Pregnant or breastfeeding women.
* Having received immunotherapy with hymenoptera venom during the 5 years prior to the start of the study.
* Participants who do not agree to participate and/or do not sign the informed consent form.
* Participants who do not comply with medical indications or do not cooperate with immunotherapy treatment.

Where it's running

• Hospital Universitario Fundación Alcorcón
  Alcorcón, Madrid, Spain Recruiting
• Hospital Reina Sofía
  Córdoba, Spain Recruiting
• Hospital Universitario de Guadalajara
  Guadalajara, Spain Recruiting

Study contacts

• Principal investigator: Arantza Vega Castro — University of Guadalajara
• Study coordinator: Miguel Casanovas
• Email: mcasanovas@inmunotek.com
• Phone: +34 91208942

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating the safety of immunotherapy for insect venom allergy

  This study is testing the safety of a new treatment for people aged 14 and older with insect venom allergies to see how well it works and if it causes any side effects.

  Recruiting at 8 sites Inmunotek S.L. · Ferrol, A Coruña and 8 other locations · NCT06782217

• Mannan-Conjugated Allergoids for House Dust M mite Allergy

  A new treatment named EP-088_MM09 is being tested to see if it can reduce nasal and eye allergy symptoms (and possibly asthma) in people aged 12 to 65 who are allergic to house dust mites, compared with a placebo.

  Recruiting at 2 sites Phase 3 Inmunotek S.L. · Covilha, Castelo Branco District and 15 other locations · NCT07904195

• Mannan-conjugated Allergoids for House Dust Mite Allergy

  A new treatment called EP-088_MM09 is being tested to see if it can reduce allergy symptoms in people with house dust mite–related nasal allergy, with or without mild asthma.

  Recruiting at 4 sites Phase 3 Inmunotek S.L. · Coimbra and 15 other locations · NCT07904052

• Sublingual MM09 for dust-mite–triggered rhinitis and rhinoconjunctivitis in people aged 12–65 with or without mild-to-moderate asthma

  This trial will test whether daily sublingual MM09 reduces symptoms and the need for rescue medication in people aged 12–65 who have rhinitis or rhinoconjunctivitis caused by dust mites, with or without mild-to-moderate asthma.

  Recruiting at 14 sites Phase 3 Inmunotek S.L. · Nueve de Julio, Buenos Aires and 18 other locations · NCT07348302

• Standardizing allergen extracts from Quercus ilex and Quercus robur

  This study is testing how strong allergen extracts from two types of oak trees are to help people with allergies by using skin tests and blood samples.

  Recruiting Inmunotek S.L. · Madrid · NCT05532566

• Evaluating a new treatment for allergies to certain trees and grasses

  This study is testing a new allergy treatment for people aged 12 to 65 who are sensitive to certain tree and grass pollens to see if it can help reduce their allergy symptoms.

  Recruiting at 9 sites Phase 3 Inmunotek S.L. · Valladolid, Castille and León and 26 other locations · NCT04898283

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.